Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort

Diabetes Pearl from the Parelsnoer Initiative; S van Oort; F Rutters; M F Warlé-van Herwaarden; M T Schram; C D Stehouwer; C J Tack; E J Abbink; B H Wolffenbuttel; M M van der Klauw; J H DeVries; S E Siegelaar; E J Sijbrands; B Özcan; H W de Valk; B Silvius; M A Schroijen; I M Jazet; A J van Ballegooijen; J W J Beulens; P J Elders; C Kramers

doi:10.1111/dme.14406

Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort

Diabetes Pearl from the Parelsnoer Initiative, S van Oort^*, F Rutters, M F Warlé-van Herwaarden, M T Schram, C D Stehouwer, C J Tack, E J Abbink, B H Wolffenbuttel, M M van der Klauw, J H DeVries, S E Siegelaar, E J Sijbrands, B Özcan, H W de Valk, B Silvius, M A Schroijen, I M Jazet, A J van Ballegooijen, J W J BeulensP J Elders, C Kramers

^*Corresponding author for this work

Life Course Epidemiology (LCE)

Research output: Contribution to journal › Article › Academic › peer-review

15 Citations (Scopus)

85 Downloads (Pure)

Abstract

AIM: To describe the prevalence and characteristics of polypharmacy in a Dutch cohort of individuals with type 2 diabetes.

METHODS: We included people with type 2 diabetes from the Diabetes Pearl cohort, of whom 3886 were treated in primary care and 2873 in academic care (secondary/tertiary). With multivariable multinomial logistic regression analyses stratified for line of care, we assessed which sociodemographic, lifestyle and cardiometabolic characteristics were associated with moderate (5-9 medications) and severe polypharmacy (≥10 medications) compared with no polypharmacy (0-4 medications).

RESULTS: Mean age was 63 ± 10 years, and 40% were women. The median number of daily medications was 5 (IQR 3-7) in primary care and 7 (IQR 5-10) in academic care. The prevalence of moderate and severe polypharmacy was 44% and 10% in primary care, and 53% and 29% in academic care respectively. Glucose-lowering and lipid-modifying medications were most prevalent. People with severe polypharmacy used a relatively large amount of other (i.e. non-cardiovascular and non-glucose-lowering) medication. Moderate and severe polypharmacy across all lines of care were associated with higher age, low educational level, more smoking, longer diabetes duration, higher BMI and more cardiovascular disease.

CONCLUSIONS: Severe and moderate polypharmacy are prevalent in over half of people with type 2 diabetes in primary care, and even more in academic care. People with polypharmacy are characterized by poorer cardiometabolic status. These results highlight the significance of polypharmacy in type 2 diabetes.

Original language	English
Article number	e14406
Number of pages	10
Journal	Diabetic Medicine
Volume	38
Issue number	4
Early online date	22-Sept-2020
DOIs	https://doi.org/10.1111/dme.14406
Publication status	Published - Apr-2021

Access to Document

10.1111/dme.14406Licence: CC BY-NC

Characteristics associated with polypharmacy in people with type 2 diabetes the Dutch Diabetes Pearl cohortFinal publisher's version, 371 KBLicence: CC BY-NC

Handle.net

Persistent link

Cite this

Diabetes Pearl from the Parelsnoer Initiative, van Oort, S., Rutters, F., Warlé-van Herwaarden, M. F., Schram, M. T., Stehouwer, C. D., Tack, C. J., Abbink, E. J., Wolffenbuttel, B. H., van der Klauw, M. M., DeVries, J. H., Siegelaar, S. E., Sijbrands, E. J., Özcan, B., de Valk, H. W., Silvius, B., Schroijen, M. A., Jazet, I. M., van Ballegooijen, A. J., ... Kramers, C. (2021). Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort. Diabetic Medicine, 38(4), Article e14406. https://doi.org/10.1111/dme.14406

@article{7bb7202c42ea4bf489aadb4dae9c7b6e,

title = "Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort",

abstract = "AIM: To describe the prevalence and characteristics of polypharmacy in a Dutch cohort of individuals with type 2 diabetes.METHODS: We included people with type 2 diabetes from the Diabetes Pearl cohort, of whom 3886 were treated in primary care and 2873 in academic care (secondary/tertiary). With multivariable multinomial logistic regression analyses stratified for line of care, we assessed which sociodemographic, lifestyle and cardiometabolic characteristics were associated with moderate (5-9 medications) and severe polypharmacy (≥10 medications) compared with no polypharmacy (0-4 medications).RESULTS: Mean age was 63 ± 10 years, and 40% were women. The median number of daily medications was 5 (IQR 3-7) in primary care and 7 (IQR 5-10) in academic care. The prevalence of moderate and severe polypharmacy was 44% and 10% in primary care, and 53% and 29% in academic care respectively. Glucose-lowering and lipid-modifying medications were most prevalent. People with severe polypharmacy used a relatively large amount of other (i.e. non-cardiovascular and non-glucose-lowering) medication. Moderate and severe polypharmacy across all lines of care were associated with higher age, low educational level, more smoking, longer diabetes duration, higher BMI and more cardiovascular disease.CONCLUSIONS: Severe and moderate polypharmacy are prevalent in over half of people with type 2 diabetes in primary care, and even more in academic care. People with polypharmacy are characterized by poorer cardiometabolic status. These results highlight the significance of polypharmacy in type 2 diabetes.",

author = "{Diabetes Pearl from the Parelsnoer Initiative} and {van Oort}, S and F Rutters and {Warl{\'e}-van Herwaarden}, {M F} and Schram, {M T} and Stehouwer, {C D} and Tack, {C J} and Abbink, {E J} and Wolffenbuttel, {B H} and {van der Klauw}, {M M} and DeVries, {J H} and Siegelaar, {S E} and Sijbrands, {E J} and B {\"O}zcan and {de Valk}, {H W} and B Silvius and Schroijen, {M A} and Jazet, {I M} and {van Ballegooijen}, {A J} and Beulens, {J W J} and Elders, {P J} and C Kramers",

note = "{\textcopyright} 2020 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.",

year = "2021",

month = apr,

doi = "10.1111/dme.14406",

language = "English",

volume = "38",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley",

number = "4",

}

Diabetes Pearl from the Parelsnoer Initiative, van Oort, S, Rutters, F, Warlé-van Herwaarden, MF, Schram, MT, Stehouwer, CD, Tack, CJ, Abbink, EJ, Wolffenbuttel, BH , van der Klauw, MM, DeVries, JH, Siegelaar, SE, Sijbrands, EJ, Özcan, B, de Valk, HW, Silvius, B, Schroijen, MA, Jazet, IM, van Ballegooijen, AJ, Beulens, JWJ, Elders, PJ & Kramers, C 2021, 'Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort', Diabetic Medicine, vol. 38, no. 4, e14406. https://doi.org/10.1111/dme.14406

TY - JOUR

T1 - Characteristics associated with polypharmacy in people with type 2 diabetes

T2 - the Dutch Diabetes Pearl cohort

AU - Diabetes Pearl from the Parelsnoer Initiative

AU - van Oort, S

AU - Rutters, F

AU - Warlé-van Herwaarden, M F

AU - Schram, M T

AU - Stehouwer, C D

AU - Tack, C J

AU - Abbink, E J

AU - Wolffenbuttel, B H

AU - van der Klauw, M M

AU - DeVries, J H

AU - Siegelaar, S E

AU - Sijbrands, E J

AU - Özcan, B

AU - de Valk, H W

AU - Silvius, B

AU - Schroijen, M A

AU - Jazet, I M

AU - van Ballegooijen, A J

AU - Beulens, J W J

AU - Elders, P J

AU - Kramers, C

PY - 2021/4

Y1 - 2021/4

N2 - AIM: To describe the prevalence and characteristics of polypharmacy in a Dutch cohort of individuals with type 2 diabetes.METHODS: We included people with type 2 diabetes from the Diabetes Pearl cohort, of whom 3886 were treated in primary care and 2873 in academic care (secondary/tertiary). With multivariable multinomial logistic regression analyses stratified for line of care, we assessed which sociodemographic, lifestyle and cardiometabolic characteristics were associated with moderate (5-9 medications) and severe polypharmacy (≥10 medications) compared with no polypharmacy (0-4 medications).RESULTS: Mean age was 63 ± 10 years, and 40% were women. The median number of daily medications was 5 (IQR 3-7) in primary care and 7 (IQR 5-10) in academic care. The prevalence of moderate and severe polypharmacy was 44% and 10% in primary care, and 53% and 29% in academic care respectively. Glucose-lowering and lipid-modifying medications were most prevalent. People with severe polypharmacy used a relatively large amount of other (i.e. non-cardiovascular and non-glucose-lowering) medication. Moderate and severe polypharmacy across all lines of care were associated with higher age, low educational level, more smoking, longer diabetes duration, higher BMI and more cardiovascular disease.CONCLUSIONS: Severe and moderate polypharmacy are prevalent in over half of people with type 2 diabetes in primary care, and even more in academic care. People with polypharmacy are characterized by poorer cardiometabolic status. These results highlight the significance of polypharmacy in type 2 diabetes.

AB - AIM: To describe the prevalence and characteristics of polypharmacy in a Dutch cohort of individuals with type 2 diabetes.METHODS: We included people with type 2 diabetes from the Diabetes Pearl cohort, of whom 3886 were treated in primary care and 2873 in academic care (secondary/tertiary). With multivariable multinomial logistic regression analyses stratified for line of care, we assessed which sociodemographic, lifestyle and cardiometabolic characteristics were associated with moderate (5-9 medications) and severe polypharmacy (≥10 medications) compared with no polypharmacy (0-4 medications).RESULTS: Mean age was 63 ± 10 years, and 40% were women. The median number of daily medications was 5 (IQR 3-7) in primary care and 7 (IQR 5-10) in academic care. The prevalence of moderate and severe polypharmacy was 44% and 10% in primary care, and 53% and 29% in academic care respectively. Glucose-lowering and lipid-modifying medications were most prevalent. People with severe polypharmacy used a relatively large amount of other (i.e. non-cardiovascular and non-glucose-lowering) medication. Moderate and severe polypharmacy across all lines of care were associated with higher age, low educational level, more smoking, longer diabetes duration, higher BMI and more cardiovascular disease.CONCLUSIONS: Severe and moderate polypharmacy are prevalent in over half of people with type 2 diabetes in primary care, and even more in academic care. People with polypharmacy are characterized by poorer cardiometabolic status. These results highlight the significance of polypharmacy in type 2 diabetes.

U2 - 10.1111/dme.14406

DO - 10.1111/dme.14406

M3 - Article

C2 - 32961611

SN - 0742-3071

VL - 38

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 4

M1 - e14406

ER -

Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort

Abstract

Access to Document

Handle.net

Fingerprint

Cite this